Merestinib,1206801-37-7

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Merestinib dihydrochloride

CAS No. : 1206801-37-7

MCE 国际站：Merestinib dihydrochloride

产品活性：Merestinib dihydrochloride (LY2801653 dihydrochloride) 是一种有效的口服生物可利用的具有抗肿瘤活性的 c-Met 抑制剂 (K_i=2 nM)。Merestinib dihydrochloride 对 MST1R (IC₅₀=11 nM)、FLT3 (IC₅₀=7 nM)、AXL (IC₅₀=2 nM)、MERTK (IC₅₀=10 nM)、TEK (IC₅₀=63 nM)、ROS1、DDR1/2 (IC₅₀=0.1/7 nM) 和 MKNK1/2 (IC₅₀=7 nM) 也有较强的活性。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：c-Met/HGFR  |  FLT3  |  ROS Kinase  |  Discoidin Domain Receptor

In Vitro: Merestinib (LY2801653) also inhibits MST1R (IC₅₀=11 nM), AXL (IC₅₀=2 nM), MERTK (IC₅₀=10 nM), TYRO3 (IC50=28 nM), ROS1, PDGFRA (IC50=41 nM), FLT3 (IC₅₀=7 nM), TEK (IC50=63 nM), DDR1/2 (IC₅₀=0.1/7 nM) and MKNK1/2 (IC₅₀=7 nM).
Merestinib demonstrates effects on MET pathway-dependent cell scattering and cell proliferation. The mean IC₅₀ value (n=6 determinations) of Merestinib for inhibition of MET auto-phosphorylation in HGF-stimulated H460 cells is 35.2±6.9 nM and the IC₅₀ for MET auto-phosphorylation in S114 cells is 59.2 nM. Transfection with the MET variants confers growth-factor independence and treatment with Merestinib inhibits growth of these MET variant clones with an IC₅₀ ranging from 3-fold more potent (V1092I) to approximately 6-fold less potent (L1195V) compare with the growth inhibition of cells with the MET wild-type sequence.
Merestinib (2, 5, and 10 μM) reduces the number of viable TFK-1 and SZ-1 cells in a dose and time dependent manner, and significant inhibits wound healing for TFK-1 and SZ-1 cell lines. Merestinib inhibits cell invasion in TFK-1 and SZ-1 cells in a concentration dependent manner.

In Vivo: Merestinib (LY2801653) demonstrates anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects. Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a pharmacodynamic residence time (K_off) of 0.00132 min^-1 and t_1/2 of 525 min. Merestinib (LY2801653) treatment inhibits MET phosphorylation with a composite TED50 (50 % target inhibition dose) of 1.2 mg/kg and a composite TED90 (90 % target inhibition dose) of 7.4 mg/kg. Merestinib (LY2801653) (20 mg/kg) reduces TFK-1 tumor growth significantly relative to vehicle control. Merestinib (LY2801653) inhibits the growth of intra- and extrahepatic CCC xenograft tumors.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Heterocyclic Compound Library  |  Mitochondrial Protection Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cytokine Inhibitors Library  |  Sorafenib  |  Afatinib  |  Cabozantinib  |  Crizotinib  |  Gilteritinib  |  Lorlatinib  |  Capmatinib  |  Quizartinib  |  Entrectinib  |  Pacritinib  |  Crenolanib  |  Fostamatinib  |  R406  |  Linifanib  |  Foretinib  |  Savolitinib  |  Emavusertib  |  Rebastinib  |  MitoPQ  |  Ripretinib  |  AT9283  |  Repotrectinib  |  Cucurbitacin B  |  Dovitinib  |  KW-2449  |  Sitravatinib  |  DDR1-IN-1  |  Mefloquine hydrochloride  |  (E/Z)-Zotiraciclib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds